Ubrogepant

What ubrogepant is

Ubrogepant is a calcitonin gene-related peptide (CGRP) receptor antagonist. The Ubrelvy label indicates it for acute treatment of migraine with or without aura in adults. The label’s limitation of use states that it is not indicated for prevention. It comes as a tablet. The dose comes from the label or the prescriber, and the label changes it for some liver, kidney and drug-interaction situations. Approval differs by country.

Results at 2 hours

The label reports two placebo-controlled trials: two doses in Study 1 and one dose in Study 2. Patients chose their most bothersome symptom from light sensitivity, sound sensitivity or nausea.

Trial	Pain freedom, ubrogepant	Pain freedom, placebo	Most bothersome symptom gone, ubrogepant	Most bothersome symptom gone, placebo
Study 1	19.2% and 21.2%	11.8%	38.6% and 37.7%	27.8%
Study 2	21.8%	14.3%	38.9%	27.4%

Each arm had between 420 and 464 patients. In Study 1, the two percentages come from the two doses, and the higher pain-freedom figure came from the higher dose.

Contraindications

The label lists two:

• use with strong CYP3A4 inhibitors;
• a history of serious hypersensitivity to ubrogepant or a component of the tablet.

Strong CYP3A inducers are also to be avoided, because the label expects a loss of efficacy. Moderate and weak CYP3A4 inhibitors, moderate and weak inducers, and BCRP or P-gp inhibitors lead to dose changes. A doctor or pharmacist can check a medicine list for these.

Warnings and special groups

• Hypersensitivity. The label says to stop ubrogepant and treat if a serious or severe reaction occurs.
• Hypertension. New and worsening high blood pressure has been reported with CGRP antagonists.
• Raynaud’s phenomenon. The label says to stop ubrogepant if signs or symptoms develop.
• Kidney. The label says to avoid use in end-stage renal disease.
• Pregnancy. The label reports no adequate human data on developmental risk and says animal data suggest possible fetal harm.
• Children. Safety and effectiveness have not been established.

The most common adverse reactions were nausea and somnolence. The label states that the safety of treating more than a set number of migraines in 30 days has not been established; the number is in the label.

Monthly limit

ICHD-3 was published in 2018, and its section 8.2 does not name gepants. Its general subtype 8.2.8 covers other acute medicines used on 10 or more days a month for more than 3 months. A 2021 American Headache Society consensus statement found that frequent use of rimegepant or ubrogepant does not appear to lead to medication-overuse headache. A 2024 commentary called the evidence inconclusive, because trials followed patients for at most 52 weeks (Pellesi 2024).

Neither the medication days counter nor Aurora counts ubrogepant against an ICHD-3 limit. This does not mean any frequency is safe. The background is under gepants and lasmiditan.

In a headache diary

Count the attacks treated in each 30 days, as well as the days, because that is the unit the label uses. For each attack, note pain at 2 hours, your most bothersome symptom, and any drowsiness or nausea. Add new medicines with their start date, so that an interaction can be checked.